All In Biotech

Drug Trial Radar · NCT06634589

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 27, 2024

Primary completion

Dec 2, 2028

Study completion Dec 2, 2029

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Oct 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.

Conditions

  • B-cell Malignancy
  • Relapsed Cancer
  • Refractory Cancer
  • B-cell Lymphoma

Interventions

  • TacabrutidegDrug

    Administered orally

  • SonrotoclaxDrug

    Administered orally

  • ZanubrutinibDrug

    Administered orally

  • MosunetuzumabDrug

    Administered subcutaneously

  • GlofitamabDrug

    Administered intravenously

  • ObinutuzumabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Substudy 1 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
  2. Substudy 1 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
  3. Substudy 2 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
  4. Substudy 2 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
  5. Substudy 3 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
  6. Substudy 3 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years]
  7. Substudy 4 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
  8. Substudy 4 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years

Locations

49 sites in 8 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Phoenix

    Phoenix, Arizona · Recruiting

  • University of Southern California Norris Comprehensive

    Los Angeles, California · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • The University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Icahn School of Medicine At Mount Sinai

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Weill Cornell Medical College Newyork Presbyterian Hospital

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • St George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • Mater Cancer Care Centre

    South Brisbane, Queensland, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Hospital Sirio Libanes Brasilia

    Brasília, Brazil · Recruiting

  • Ensino E Terapia de Inovacao Clinica Amo Etica

    Salvador, Brazil · Recruiting

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

    São José do Rio Preto, Brazil · Recruiting

  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

    São Paulo, Brazil · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

  • Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden

    Dresden, Germany · Recruiting

  • Universitatsklinikum Jena Klinik Fur Innere Medizin Ii

    Jena, Germany · Recruiting

  • Universitatsklinikum Schleswig Holstein Campus Kiel

    Kiel, Germany · Recruiting

  • Medizinische Universitaetsklinik

    Tübingen, Germany · Recruiting

  • Universitaetsklinikum Ulm

    Ulm, Germany · Recruiting

  • Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi

    Bologna, Italy · Recruiting

  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

    Milan, Italy · Recruiting

  • Istituto Nazionale Tumori Fondazione G Pascale

    Naples, Italy · Recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.